APP
COGT icon

Alpha Paradigm Partners’s Cogent Biosciences COGT Stock Holding History

Alpha Paradigm Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-76,348
Closed -$1.14M – 502
2022
Q3 		$1.14M Buy
+76,348
New +$1.05M 0.49% 52

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Alpha Paradigm Partners's COGT Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Cogent Biosciences (COGT) in Q4 2022, closing a stake of 76,348 shares — an estimated $1.14M sold.

Alpha Paradigm Partners first reported a position in COGT in Q3 2022 and held it in 1 quarter. The position peaked at $1.14M in Q3 2022. 135 funds tracked by Wall St. Rank hold COGT as of Q4 2022.

  • Alpha Paradigm Partners reported no remaining Cogent Biosciences position as of Q4 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 76,348 Cogent Biosciences shares in Q4 2022, an estimated $1.14M.
  • Alpha Paradigm Partners first reported a position in Cogent Biosciences in Q3 2022 and held it in 1 quarter.
  • Alpha Paradigm Partners's Cogent Biosciences position peaked at $1.14M in Q3 2022.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.